ÐÂÎŶ¯Ì¬

ÒýÑÔ

        תÒÆÐÔÈ¥ÊƵֿ¹ÐÔÇ°ÁÐÏÙ°©£¨metastatic castration-resistant prostate cancer£¬mCRPC£©ÊÇÇ°ÁÐÏÙ°©£¨prostate cancer£¬PCa£©·¢Õ¹µÄÖÕÄ©½×¶Î£¬»¼ÕßÔ¤ºó¼«²î£¬Ê¹Óô«Í³ÖÎÁÆÊÖ¶ÎÈ绯ÁÆ¡¢ÄÚ·ÖÃÚÖÎÁƵÈÁÆЧÓÐÏÞ¡£Ø½Ðè¸ü¾«×¼¡¢¸ßЧµÄÖÎÁÆ·½°¸À´¸ÄÉÆ»¼ÕßÉú´æÖÊÁ¿ÓëÑÓ³¤Éú´æÆÚ£¬ÇҾݸ¥Èô˹ÌØɳÀûÎÄÔ¤²â£¬2030ÄêÈ«ÇòmCRPC »¼²¡Êý½«´ï208ÍòÀý£¬»¼ÕßȺÌåÅÓ´ó¡£

        2022Ä꣬°ÐÏòÇ°ÁÐÏÙÌØÒìÐÔĤ¿¹Ô­£¨prostate specific membrane antigen£¬PSMA£©µÄ·ÅÉäÐÔÅäÌåÁÆ·¨Pluvicto^@£¨¹⁷⁷Lu-PSMA-617£©µÄ»ñÅú£¬ÎªmCRPC»¼Õß´øÀ´ÁËеÄÏ£Íû£¬Ê¹mCRPCµÄÖÎÁÆÓÐÁËÀï³Ì±®½øÕ¹¡£´óÁ¿µÄÁÙ´²ÊÔÑéÊý¾ÝÖ¤Ã÷£¬È·¶¨»¼ÕßPSMAÑôÐÔ¶ÔÓÚPluvicto^@µÄ°ÐÏòÖÎÁÆÖÁ¹ØÖØÒª¡£Òò´Ë£¬ÔÚPluvicto^@½øÐаÐÏòÖÎÁÆÇ°£¬½«Ê¹ÓÃPSMAÕýµç×Ó·¢Éä¶Ï²ãɨÃè½øÐзÖ×ÓÓ°ÏñÈ·Ö¤¡£È»¶ø×ÛºÏÁÙ´²ÁÆЧÊý¾ÝÀ´¿´£¬ÈÔÓÐÔ¼30%µÄmCRPC»¼Õ߶ÔPluvicto^@ÖÎÁÆÎÞ·´Ó¦¡£ÕâÒâζ×Å£¬¾¡¹Ü¸ÃÁÆ·¨¿Éʹ²¿·Ö»¼Õß»ñÒ棬µ«ÈÔÓдóÁ¿»¼ÕßδÄÜ¿çÔ½ÖÎÁÆÏìÓ¦µÄÃż÷£¬¼«´óÏÞÖÆÁËÆäÁÆЧµÄ·¢»Ó£¬Õâ¿ÉÄܹéÒòÓÚPSMAµÄ±í´ïÒìÖÊÐÔ»òȱʧ^[1]¡£Òò´Ë£¬ÉîÈë̽¾¿ÕâÒ»ÏÖÏóµÄµ×²ãÂß¼­£¬Ñ°ÕÒµÄÆƾÖ֮·£¬³ÉΪµ±Ç°ÁÙ´²Óë¿ÆÑÐÁìÓòµÄÖØÒª¿ÎÌâ¡£ 

        ±¾ÎĽ«´ÓmCRPC»¼Õ߶ÔPluvicto^@ÖÎÁÆδÍêÈ«·´Ó¦ÕâÒ»ÁÙ´²ÎÊÌâ³ö·¢£¬ÏÈϵͳ·ÖÎöµ¼ÖÂÎÞ·´Ó¦µÄÔ­Òò£¬°üÀ¨PSMA±í´ïÒìÖÊÐÔ¡¢±í´ïˮƽ²»×ã¼°ÖÎÁÆÖж¯Ì¬Ï½µµÈ£»Ëæºó£¬Ïêϸ²ûÊöÄ¿Ç°Õë¶ÔÕâЩԭÒòµÄÓ¦¶Ô²ßÂÔ£¬°üÀ¨ÁªºÏÓÃÒ©¡¢¸ü»»ºËËؼ°¿ª·¢Ë«ÌØÒìÐÔ·ÅÉäÐÔºËËØÅäÌåµÈ£¬Ö¼ÔÚΪÉîÈëÀí½âÕâÒ»ÖÎÁÆÄÑÌâÒÔ¼°Ì½Ë÷ÓÐЧµÄ½â¾ö·½°¸ÌṩÇåÎúµÄ˼·Óë·½Ïò¡£

 

1¡¢ÎªºÎÔ¼30%µÄmCRPC»¼Õ߶ÔPluvicto^@ÖÎÁÆÎÞ·´Ó¦£¿

1.1 PSMA±í´ïµÄÒìÖÊÐÔ

        Õë¶ÔPSMAµÄ°ÐÏòÖÎÁÆ£¨È磺·ÅÉäÐÔÅäÌåÁÆ·¨£¨Radioligand Therapy£¬RLT£©£©Ö÷ÒªÒÀÀµÓÚ PSMAµÄ±í´ïÀ´·¢»Ó×÷Óã¬ÈôÖ×ÁöÖдæÔÚ´óÁ¿µÍ/²»±í´ïPSMAµÄϸ°û£¬ÕâЩϸ°û¿ÉÄÜÌÓ±ÜÖÎÁÆ£¬µ¼ÖÂÖ×Áö²ÐÁô»ò¸´·¢£¬´Ó¶ø½µµÍÖÎÁÆÏìÓ¦ÂÊ£¬ÕâÒ²ÊÇÁÙ´²ÖÐÐèÒª¹Ø×¢Ö×ÁöÄÚ²¿±êÖ¾Îï±í´ï²îÒì¡¢ÓÅ»¯ÖÎÁÆ·½°¸µÄÖØÒªÔ­ÒòÖ®Ò»¡£PSMA ±í´ïÒìÖÊÐÔµÄÌصã´æÔÚ¶à²ã¸´ÔÓÐÔ£¬Èç¿ÉÒÔÔÚϸ°û¡¢Ö×Áö»ò¿Õ¼ä¡¢»¼Õ߼䡢»¼ÕßÄÚ¡¢Æ×ϵÄÚ¡¢Æ×ϵ¼äºÍʱ¼äά¶È¹Û²ìµ½£¨¼ûͼ1£©¡£

        ϸ°ûÒìÖÊÐÔÊÇÖ¸µ¥¸öÖ×Áöϸ°ûÄڵıäÒìÐÔ£¬Æä»áËæ×Åʱ¼äµÄÍÆÒƶøÑݱ䣬ÓÖ³ÆΪʱ¼äϸ°ûÒìÖÊÐÔ¡£¿Õ¼ä»òÖ×ÁöÄÚÒìÖÊÐÔÃèÊöÁËͬһÖ×ÁöÔÚ²»Í¬ÇøÓòÄڵıäÒìÐÔ.¡£»¼ÕßÄÚÒìÖÊÐÔ²¶×½ÁËͬһ»¼ÕßÌåÄÚ¶à¸öÖ×ÁöÖ®¼äµÄ±äÒ죬Ó뻼Õß¼äÒìÖÊÐÔÐγÉÏÊÃ÷¶Ô±È£¬ºóÕßÊDz»Í¬¸öÌåÖ®¼äÖ×ÁöµÄ±äÒìÐÔ¡£¶øÆ×ϵÄÚÒìÖÊÐÔ²àÖØÓÚͬһ»¼ÕßÄÚµ¥Ï¸°ûÆ×ϵÄÚËæʱ¼äµÄ±ä»¯£¬ÕâÇ¿µ÷ÁËPCaÖÐ PSMA ±í´ïµÄ¶¯Ì¬ÐÔÖÊÒÔ¼°Ï¸ÖÂÈë΢µÄÖÎÁÆ·½·¨µÄ±ØÒªÐÔ¡£ÓÐÎÄÏ×½øÒ»²½ÑéÖ¤ÁËPSMA±í´ïÒìÖÊÐԵĴæÔÚ£¬ÔÚ¶Ô52ÀýmCRPC»¼ÕßµÄ636¸öתÒÆÔîÑù±¾½øÐзÖÎöʱ·¢ÏÖ£¬ÕâЩתÒÆÔîÖÐPSMAµÄ±í´ïÖ÷Òª·ÖΪ3ÖÖģʽ£º25%µÍ/ÒõÐÔ£¨H-score≤20£©¡¢44%ÒìÖÊÐÔ£¨Í¬Ê±°üº¬µÍ/ÒõÐԺ͸߱í´ïתÒÆÔ¡¢31%¸ß±í´ï£¨H-score>20£©^[2]¡£Í¬Ê±£¬²¿·ÖmCRPC»¼ÕßµÄÖ×Áöϸ°ûPSMA±í´ïˮƽ¼«µÍ£¬ÉõÖÁ²»±í´ï£¬¶øÇÒÔÚµ¥¸öתÒÆÔîÇÐƬÖÐÒ²¿ÉÒԹ۲쵽PSMA±í´ï¸ßµÍ²»Í¬µÄÇøÓò£¬Õâ˵Ã÷×÷ΪPSMAµÄ°ÐÏòÒ©Pluvicto^@ÎÞ·¨ÌØÒìÐÔµØʶ±ð²¢½áºÏËùÓÐÖ×Áöϸ°û£¬×ÔȻҲ¾ÍÄÑÒÔ¾¡È«Á¦ÖÎÓúÕû¸öÖ×Áö¡£

ͼ1  ²»Í¬Ë®Æ½PSMA±í´ïÒìÖÊÐÔʾÒâͼ

 

1.2 PSMAµÄ±í´ïˮƽ²»×ã

        ÓëPSMA±í´ïÒìÖÊÐÔ²»Í¬µÄÊÇ£¬PSMA ±í´ïˮƽ²»×ãÒ²Êǵ¼Ö Pluvicto^®ÖÎÁÆÏìÓ¦ÂÊÊÜÏÞµÄÖØÒªÔ­Òò¡£ÓÐÑо¿¶Ô85Àý½ÓÊܹ⁷⁷Lu-PSMA-617ÖÎÁƵĻ¼Õß½øÐзÖÎö£¨ËùÓл¼Õß¾ù½ÓÊÜÁËÖÎÁÆÇ°⁶⁸Ga-PSMA-PET-CTɨÃ裩^[3]£¬½á¹û·¢ÏÖPSMAƽ¾ù±í´ïˮƽ¸ßµÄ»¼Õß±ÈPSMAƽ¾ù±í´ïˮƽµÍµÄ»¼ÕßÉú´æÆÚ¸ü³¤£¨15.1¸öÔ vs 5.3¸öÔ£¬¼ûͼ2£©£¬×ªÒÆÔîPSMA±í´ïˮƽ½ÏµÍ»¼ÕßÏà±È±í´ïˮƽ½Ï¸ß»¼ÕßµÄÉú´æÆÚ¸ü¶Ì£¨7.9¸öÔ vs 21.3¸öÔ£©£¬Õâ±íÃ÷¸ß PSMA ±í´ï»¼Õß½ÓÊܹ⁷⁷Lu-PSMA-617ÖÎÁƺóÉú´æÆÚÄܵõ½ÏÔÖøÑÓ³¤£¬¶øPSMA±í´ïˮƽ²»×ãÔò»áÑÏÖØÓ°ÏìÖÎÁÆЧ¹û¡£

ͼ2  »ùÓÚ²»Í¬PSMA-PET²ÎÊýµÄ¶þÖµ»¯·Ö×é½á¹ûÓë×ÜÌåÉú´æÂÊ£¬×¢£ºPSMAmax£¨×î¸ßPSMA±í´ïתÒÆÔîµÄSUVmax£©¡¢PSMAmin£¨×îµÍPSMA±í´ïתÒÆÔîµÄSUVmax£©¡¢PSMAaverage£¨ËùÓÐתÒÆÔîµÄƽ¾ùSUVmax£©£»²ÉÓÃLog-rank½Ø¶ÏÖµ²éÕÒÆ÷È·¶¨µÍPSMAƽ¾ùÖµ£¨lowPSMAaverage£©ºÍ¸ßPSMAƽ¾ùÖµ£¨highPSMAaverage£©£¬ÒÔ¼°µÍPSMA×îСֵ£¨lowPSMAmin£©ºÍ¸ßPSMA×îСֵ£¨highPSMAmin£©

 

1.3 ÖÎÁÆÖÐPSMA±í´ï¶¯Ì¬Ï½µ

        Ò©´ú¶¯Á¦Ñ§/ҩЧ¶¯Á¦Ñ§£¨PK/PD£©Ä£ÐÍ֤ʵ£¬ÖÎÁÆÖÜÆÚÄÚÖ×Áö¶Ô¹⁷⁷Lu-PSMA-I&TµÄÉãÈ¡Á¿³Ê½øÐÐÐÔϽµ£¬µ¼ÖºóÐøÖÎÁÆÁÆЧ˥¼õ^[4]¡£ÕâÖÖ¶¯Ì¬±ä»¯¿ÉÄÜÓëÖ×Áöϸ°ûËÀÍöºÍ/»òPSMAÊÜÌå±í´ïϽµÏà¹Ø¡£ÆÀ¹À·ÅÁƺóPCa²¡ÔîÖÐ PSMAµÄPET/CT ɨÃèÐźŵĶ¯Á¦Ñ§±ä»¯·¢ÏÖ£¬ÊÜÕÕÉ䲡ÔîÖÐµÄ PSMA ÉãÈ¡Á¿»áËæ×Åʱ¼äÖð½¥Ï½µ£¬Í¨³£ÔÚÖÎÁƺó9ÖÁ12¸öÔ´ﵽ×îµÍˮƽ¡£ÕâÓë·ú´úÍÑÑõÆÏÌÑÌÇ£¨¹⁸F-FDG£©PET ÐγɶԱȣ¬¹⁸F-FDGÉãÈ¡Á¿Í¨³£ÔÚ3ÖÁ4¸öÔÂÄÚ´ïµ½×îµÍµã¡£PSMA ÉãÈ¡Á¿Ï½µ½ÏÂý±íÃ÷£¬ÖÎÁƺóÔçÆÚ£¨ÓÈÆäÊÇ3¸öÔÂÄÚ£©µÄ PSMA µÄPET/CT ɨÃè¿ÉÄÜ»á¸ß¹À²ÐÁô¼²²¡£¬ÕâÓпÉÄܵ¼ÖÂÎóÕï»ò¹ý¶ÈÖÎÁÆ¡£´ËÍ⣬»¹¹Û²ìµ½Ç°ÁÐÏÙ»òÇ°ÁÐÏÙ´²²¡ÔîÖÐµÄ PSMA ÉãÈ¡Á¿Ï½µÍùÍù±È¹Ç»òÁܰͽᲡÔîÖÐµÄ PSMA ÉãÈ¡Á¿Ï½µ¸üÂý£¬ÔÚ½â¶Á·ÅÁƺóPSMA PET/CTɨÃè½á¹ûʱ£¬Ó¦¿¼Âǵ½ÕâÖÖ²¿Î»ÌØÒìÐÔ²îÒì¡£·ÅÁƺóÔ¼9¸öÔÂÈÔ³ÖÐø´æÔÚµÄÉãÈ¡ÓëËæ·ÃÓ°Ïñѧ¼ì²éÖлñµÃÍêÈ«¾Ö²¿»º½â£¨L-CR£©µÄ¿ÉÄÜÐԽϵÍÏà¹Ø£¬Õâ±íÃ÷¿ÉÄÜ´æÔÚ²ÐÁôµÄ´æ»î¼²²¡¡£Ïà·´£¬Ðí¶àÔçÆÚÓвÐÁôÉãÈ¡µÄ²¡ÔîÔÚºóÐøÓ°Ïñѧ¼ì²éÖÐÎÞÐè¶îÍâÖÎÁƾÍÏûʧÁË£¬ÕâÓë¼ÙÐÔ½øÕ¹»òÖÎÁƺóÑ×Ö¢±ä»¯Ïà·û¡£ÕâЩÑо¿½á¹ûÇ¿µ÷ÁËÔÚʹÓà PSMA PET/CTÆÀ¹ÀÖÎÁÆ·´Ó¦Ê±£¬Ñ¡ÔñºÏÊʳÉÏñʱ»úµÄÖØÒªÐÔ¡£×¼È·½â¶Á PSMA ÐźŶ¯Ì¬±ä»¯ÓÐÖúÓÚÁÙ´²Ò½Éú¸üºÃµØÆÀ¹À¾Ö²¿¿ØÖÆÇé¿ö£¬±ÜÃâ¹ýÔçÉý¼¶ÖÎÁÆ£¬²¢ÎªPCa»¼ÕßÖƶ¨×î¼Ñ¹ÜÀí²ßÂÔÌṩָµ¼¡£

 

2¡¢ÆƾֲßÂÔ

        Ϊ½â¾öÉÏÊöÖÂʹÁÙ´²ÁÆЧ²»¼ÑµÄÔ­Òò£¬×ܽá¶àÊýѧÕ߹۵㣬ÈÏΪÏÈ´Ó¾«×¼Õï¶ÏÆÀ¹ÀÈëÊÖ£¬È»ºóÓÅ»¯ÖÎÁÆ·½°¸£¬²ÉÈ¡ÁªºÏÖÎÁƺÍÑз¢ÐÂÒ©ÎïµÈÖÎÁƲßÂÔ£¬ÒÔÌá¸ßÖÎÁÆЧ¹û¡£

2.1 ¾«×¼Õï¶Ï

        ÖÎÁÆÇ°PSMAÑôÐÔ±í´ïÖ×Áö»¼ÕßµÄɸѡºÍÖÎÁƹý³ÌµÄPSMAµÄ±ä»¯¼ì²â£¬ÎªÖƶ¨ÖÎÁÆ·½°¸ºÍÖÎÁƺóµÄ·½°¸µ÷ÕûÌṩÒÀ¾Ý¡£Ä¿Ç°ÓÃÓÚɸѡµÄÒÔPET/CT ΪÖ÷£¬¶øÖÎÁƺóµÄPSMA¼ì²â¶àÓÃSPET/CT¡£

        ¢Å »ùÏßPSMA-PET/CTÈ·¶¨¹⁷⁷Lu-PSMAÁÆ·¨µÄÊÊÓÃÐÔ

        ¼ÓÖÝ´óѧ¾É½ðɽ·ÖУµÄҽѧ²©Ê¿ÍÐÂí˹?A?»ôÆÕ£¨Thomas A. Hope£©ÒÔ¼°¸Ãר¼ÒС×éµÄ³ÉÔ±Ò»ÖÂÈÏΪ£¬Ó¦Ê¹Óà VISION±ê×¼—Èç¹û»¼ÕßÖÁÉÙÓÐÒ»´¦²¡ÔîµÄPSMAÉãÈ¡¸ßÓÚ¸ÎÔ࣬Ôò·ûºÏÈëÑ¡Ìõ¼þ£»Èç¹ûÈκÎÒ»´¦²¡Ôî·ûºÏ¼ÆËã»ú¶Ï²ãɨÃ裨CT£©´óС±ê×¼£¬µ«PSMAÉãÈ¡µÍÓÚ¸ÎÔ࣬Ôò±»ÅųýÔÚÍ⣬´Ó¶øÀ´É¸Ñ¡·ûºÏÌõ¼þµÄ»¼Õß½ÓÊܹ⁷⁷Lu-PSMA-617ÖÎÁÆ¡£ÕâʹµÃ⁶⁸Ga-PSMA-11ºÍ¹⁸F-DCFPyLÕâÁ½ÖÖʾ×Ù¼Á»á¸üÊÜÇàíù£¬²»¹ýPSMA PET/ CT¼ì²âÓ¦ÔÚ¿ªÊ¼ÖÎÁÆÇ°µÄ3¸öÔÂÄÚ½øÐУ¬±ÜÃâPSMA±í´ï²îÒ졣Ϊʶ±ðDZÔÚµØPSMAÒõÐÔÖ×Áö£¬ÓÈÆäÊÇ»¼ÓиÎÔ༲²¡µÄ»¼Õߣ¬»¹Ó¦½øÐÐÔöÇ¿CT»òMRI¼ì²é¡£¸Ãר¼ÒС×é»ùÓÚ¶ÔÇ°Õ°ÐÔÊÔÑéÊý¾ÝµÄ»Ø¹Ë£¬½öÒÀÀµÓÚPSMA-PET/ CT³ÉÏñÔÚ1-9·ÖµÄÁ¿±íÉÏÆÀ¹ÀÁ˹⁷⁷Lu-PSMA-617ÔÚ¸÷ÖÖPCaÁÙ´²³¡¾°ÖеĺÏÀíʹÓÃÇé¿ö^[5]¡£¶øTheraPÔòͬʱʹÓà PSMAºÍ¹⁸F-FDG PET/CT ¶Ô»¼Õß½øÐиüÑϸñµÄɸ²é¡£TheraP ÒªÇóÖÁÉÙÓÐÒ»´¦²¡ÔîµÄ×î´ó±ê×¼ÉãÈ¡Öµ£¨SUVmax£©≥20£¬²¢Åųý¹⁸F-FDGÑôÐÔµ«PSMAÒõÐԵIJ»Ò»Ö²¡Ôî»òÈκΠSUVmax£¼10µÄ²¡ÔîµÄ»¼Õß¡£ÓÉÓÚÕâЩ¸üÑϸñµÄãÐÖµ£¬TheraPÖÐÓÐ27.4%µÄɸ²é»¼ÕßÒò²»·ûºÏ³ÉÏñ±ê×¼¶øδÈëÑ¡£¬¶ø VISION ÖÐÕâÒ»±ÈÀý½öΪ12.6%¡£TheraP ÖеÄÇ°ÁÐÏÙÌØÒìÐÔ¿¹Ô­£¨PSA£©Ï½µ50%£¨PSA₅₀£©µÄÓ¦´ðÂÊÒ²¸ü¸ß£¨66% vs 46%£©£¬Õâ¿ÉÄÜÒ²·´Ó³Á˸ü¾ßÑ¡ÔñÐÔµÄÈëÑ¡±ê×¼ºÍÖ×ÁöÉúÎïѧÌØÐÔ^[1]¡£

ͼ3 ±È½ÏVISIONºÍTheraPÁ½ÏîÁÙ´²Ñо¿µÄ·Ö×ÓÓ°ÏñµÄÈëÅűê×¼ºÍORR½á¹û

 

        ¢Æ Óõ¥¹â×Ó·¢Éä¼ÆËã»ú¶Ï²ãɨÃèSPECT/CTÅжÏÖÎÁƺóµÄЧ¹û

        һЩÑо¿Ç¿µ÷Á˹⁷⁷Lu-PSMA SPECT/CTºÍ¼ÁÁ¿²â¶¨·¨ÔÚÔ¤²âRLT»¼ÕßµÄÁÆЧµÄDZÔÚÁÙ´²Ó¦Óá£Ê×´ÎÖÎÁƺóSPECT/CT½á¹ûÏÔʾ£¬38%µÄ»¼ÕßÓëÖÎÁÆÇ°PSMA PET/CT½á¹û²»Ò»Ö£¬ÆäÖÐ93.3%»¼ÕßµÄPET/CT¼ì²éÓëÖÎÁƼä¸ô³¬¹ý30Ì죬Õâ±íÏÖÁË´Ó»ùÏßPSMA PET/CTµ½µÚÒ»¸öÖÎÁÆÖÜÆÚÆÚ¼ä³öÏÖ¼²²¡½øÕ¹µÄ»¼Õß¡£Òò´Ë£¬¶ÔÓÚÄÇЩÔÚÖÎÁÆÇ°30ÌìÒÔÉϽøÐлùÏß PSMA PET/CT¼ì²éµÄ»¼Õߣ¬Ó¦ÔÚµÚÒ»¸öÖÜÆÚºó½øÐй⁷⁷Lu-PSMAÈ«ÉíSPECT/CT¼ì²é£¬²¢½«¸Ã¼ì²é×÷ΪδÀ´±È½ÏµÄлùÏß¡£

        ÔÚ2025ÄêºËҽѧÓë·Ö×ÓÓ°Ïñѧ»á£¨SNMMI£©Äê»áÉÏ£¬Ò»ÏîÑо¿·¢ÏÖ£¬»ùÏßPSMA PET/CTÓ¦ÔÚµÚÒ»¸öÖÎÁÆÖÜÆÚºó4ÖÜÄÚÍê³É£¬²¢ÇÒÇ¿ÁÒÖ§³Ö¶Ô½ÓÊܹ⁷⁷Lu-PSMAÖÎÁƵĻ¼Õß½øÐÐÖÎÁƺóSPECT/CT¼ì²é¡£ PathmanadavelµÈÈËÔÚ¹⁷⁷Lu-PSMA -RLTµÄµÚÒ»ºÍµÚÈý¸öÖÜÆÚºó¶Ô¹⁷⁷Lu-PSMA SPECT/CT½øÐж¨Á¿·ÖÎöºó·¢ÏÖ£¬´Ó»ùÏßPSMA PET/CTÖÁ12ÖÜÆÚ¼äSPECT/CT×ÜÖ×ÁöÌå»ýÔö¼Ó30%£¬ÇÒÓëÎÞ½øÕ¹Éú´æÆÚÎ޹أ¬´Ó¶ø¿ÉÔ¤²â¼²²¡½øÕ¹¡£

2.2 ÓÅ»¯ÖÎÁÆ·½°¸

        ¢Å ·Ö²ãÖÎÁÆ

        ÒÀ¾ÝÖ×ÁöµÄPSMA PET/CT±í´ïˮƽ£¨¸ß¡¢ÖС¢µÍ£©¡¢¼²²¡·ÖÆÚ¡¢ÉíÌå×´¿öµÈÒòËضԻ¼Õß½øÐзֲã¡£PSMA¸ß±í´ïÇÒÉíÌå×´¿ö½ÏºÃµÄ»¼Õߣ¬¿É²ÉÓýϸ߼ÁÁ¿µÄ PSMA °ÐÏòÒ©Î¶ÔÓÚ PSMA µÍ±í´ï»¼Õߣ¬Êʵ±½µµÍ¼ÁÁ¿²¢ÁªºÏÆäËûÖÎÁÆÊֶΣ¬±ÜÃâ¹ý¶ÈÖÎÁÆ£¬Í¬Ê±Ìá¸ßÖÎÁƵÄÕë¶ÔÐÔ¡£

        ¢Æ ¶¯Ì¬µ÷ÕûÖÎÁÆ

        ÒÀ¾ÝÖÎÁƹý³ÌÖÐÖ×ÁöÄÚPSMA±í´ï£¨SPET/CT¼ì²â½á¹û£©µÄ±ä»¯ÊµÊ±µ÷ÕûÖÎÁÆ·½°¸¡£ÀýÈ磬ÔÚÖÎÁÆÒ»¶Îʱ¼äºó£¬Í¨¹ýÔٴγÉÏñ¼ì²âPSMA ±í´ïÏÖ×´£¬Èô·¢ÏÖÔ­±¾ PSMA ÑôÐÔµÄÖ×ÁöÇøÓòתΪÒõÐÔ£¬¿É¼õÉÙ PSMA °ÐÏòÒ©Îï¼ÁÁ¿£¬Ôö¼ÓÆäËûÕë¶ÔÒõÐÔϸ°ûµÄÖÎÁÆ·½·¨£¬È绯ÁÆ»òÃâÒßÖÎÁÆ¡£

2.3 ÍêÉÆÖÎÁÆ·½·¨

        Ä¿Ç°£¬Õë¶ÔÔ¼30%µÄ mCRPC »¼Õß¶Ô Pluvicto^@ÖÎÁÆÎÞ·´Ó¦µÄÎÊÌ⣬Ñо¿ÈËÔ±»¹¿ªÕ¹Á˶෽ÃæµÄ³¢ÊÔ£¬ÔÚÁªºÏÓÃÒ©¡¢Õë¶Ô¹ÑתÒƲ¡ÔîµÄαºËËØÒ©Î￪·¢ºÍË«°ÐµãºËËØÒ©ÎïÈý¸ö·½ÃæÓÐÃ÷ÏÔ½øÕ¹¡£

        ¢Å ÁªºÏÓÃÒ©

        ¢ÙÓëÃâÒßÖÎÁƽáºÏ£ºPRINCE phase 1ÊÔÑéÆÀ¹ÀÁ˹⁷⁷Lu-PSMA-617ÁªºÏÅÁ²©ÀûÖéµ¥¿¹µÄ°²È«ÐÔºÍÓÐЧÐÔ£¬¾ßÓÐÒ»¶¨ÁÆЧ£»EVOLUTION phase 2ÊÔÑé±È½ÏÁ˹⁷⁷Lu-PSMA-617ÁªºÏÒÁƥľµ¥¿¹ºÍÄÉÎäÀûÓȵ¥¿¹Óëµ¥¶À¹⁷⁷Lu-PSMA-617µÄЧ¹û¡£

        ¢ÚÓ뻯ÁƽáºÏ£ºLuCAB phase 1/2ÊÔÑéÆÀ¹À¹⁷⁷Lu-PSMA-617ÁªºÏ¿¨°ÍËûÈüµÄ×î´óÄÍÊܼÁÁ¿µÈ£»UpFrontPSMA phase 2ÊÔÑé±È½ÏÐò¹áʹÓù⁷⁷Lu-PSMA-617ºÍ¶àÎ÷ËûÈüÓë½öʹÓöàÎ÷ËûÈüÖÎÁÆתÒÆÐÔ¼¤ËØÃô¸ÐÐÔÇ°ÁÐÏÙ°©£¨mHSPC£©µÄÁÆЧ¡£

        ¢ÛÓë·ÅÁƽáºÏ£ºÓÐÑо¿ÔÚ̽Ë÷¹⁷⁷Lu-PSMA-617ÁªºÏÁ¢Ì嶨ÏòÌ岿·ÅÁÆÓÃÓÚ¹ÑתÒÆÐÔÈ¥ÊÆÃô¸ÐÐÔPCaµÄÓ¦Óá£

        ¢ÜÓë·Ö×Ó°ÐÏòÖÎÁƽáºÏ£ºLuPARP phase 1ÊÔÑéÆÀ¹ÀÁ˹⁷⁷Lu-PSMA-617ÁªºÏ°ÂÀ­ÅÁÀûµÄ°²È«ÐÔºÍÄÍÊÜÐÔ£»LuPIN phase 1/2ÊÔÑéÆÀ¹ÀÁ˹⁷⁷Lu-PSMA-617ÓëÒÀ´ïŵÎô¶ûµÄÁÆЧ£¬Ëä¾ßÓÐÒ»¶¨µÄЧ¹ûµ«´æÔÚ²»Á¼·´Ó¦¡£

        ¢ÝÓë²²³RaÁÆ·¨½áºÏ£ºRALU »Ø¹ËÐÔÑо¿¡¢WARMTH ¶àÖÐÐÄÑо¿µÈÏÔʾ¹⁷⁷Lu-PSMA-617ÔÚ½ÓÊܹý²²³RaCl2ÖÎÁƵĻ¼ÕßÖÐÄÍÊÜÐÔÁ¼ºÃ¡£

        ¢ÞÓëÐÛ¼¤ËØÊÜÌåͨ·ÒÖÖƼÁ½áºÏ£ºENZA-p phase 2ÊÔÑ齫mCRPC»¼ÕßËæ»ú·Ö×飬±È½Ï¶÷ÔÓ³°·µ¥Ò©Óë¶÷ÔÓ³°·ÁªºÏ¹⁷⁷Lu-PSMA-617µÄЧ¹û£¬ÁªºÏÖÎÁÆ×éÔÚÇ°ÁÐÏÙÌØÒìÐÔ¿¹Ô­ÎÞ½øÕ¹Éú´æÆÚ¡¢×ÜÉú´æÆڵȷ½Ãæ¸üÓÅ^[6]¡£

        ¢Æ ¿ª·¢alphaºËËØÒ©Îï

        Ïà½ÏÓÚβºËËØ£¬αºËËØ·¢ÉäµÄÄÜÁ¿¸ü¸ßÇÒ×÷Ó÷¶Î§¸ü¶Ì£¬Ñо¿±¨µÀÏÔʾαÉäÏßµÄÏßÐÔÄÜÁ¿´«µÝ£¨LET£©ÊÇβÉäÏßµÄ100±¶ÒÔÉÏ£¬¿ÉÒý·¢¸üÃܼ¯µÄDNAË«Á´¶ÏÁÑ£¬Äܹ»¸ü¾«×¼µØ´Ý»Ù°©Ï¸°û£¬Í¬Ê±¼õÉÙ¶ÔÁÚ½ü×éÖ¯µÄËðÉË¡£ÔÚ¹⁷⁷Lu-PSMA-617ÖÎÁƺó½øÕ¹µÄmCRPC»¼ÕßÖУ¬²²⁵Ac-PSMA-617ÈÔÄÜÓÐЧ½µµÍPSAˮƽ^[7]¡£È»¶ø£¬Ä¿Ç°αºËËع©Ó¦²»×ãÊÇÆäÃæÁÙµÄÑϾþÎÊÌâ¡£αºËËصÄÉú²úÐèÒªÌØÊâµÄºË·´Ó¦¶ÑÉèÊ©£¬²¢ÇÒÆäÉú²ú¹ý³Ì¸´ÔÓ¡¢³É±¾¸ß°º£¬ÕâʹµÃαºËËصĹ©Ó¦ÄÑÒÔÂú×ãÁÙ´²ÐèÇ󣬴ӶøÏÞÖÆÁË»ùÓÚαºËËصÄÖÎÁÆ·½·¨µÄÆÕ¼°¡£

        ¢Ç ¿ª·¢Ë«ÌØÒìÐÔÅäÌåºËËØÒ©Îï

        Éè¼ÆÄܹ»Í¬Ê±½áºÏPSMAºÍÆäËûÖ×ÁöÏà¹Ø¿¹Ô­»òÃâÒßϸ°û±íÃæ·Ö×ÓµÄË«ÌØÒìÐÔ¿¹Ì壬ÕâÑù²»½ö¿ÉÒÔÔöÇ¿¶ÔPSMAÑôÐÔÖ×Áöϸ°ûµÄ°ÐÏòÐÔ£¬»¹Äܼ¤»îÃâÒßϸ°û¶ÔÖ×Áöϸ°ûµÄɱÉË×÷Ó㬿˷þÒòPSMAÒìÖÊÐÔµ¼ÖµIJ¿·ÖÖ×Áöϸ°ûÌÓÒÝÎÊÌâ¡£²¢ÇÒÑ¡ÔñÓëPSMA±í´ï»¥²¹¡¢ÇÒÔÚPCaÖоßÓÐÃ÷È·Ö°©Çý¶¯×÷ÓõķÖ×Ӱе㣬¹¹½¨Ë«ÌØÒìÐÔÕï¶ÏÖÎÁÆÌåϵ£¬Ò²ÊÇÑо¿µÄÈȵ㡣ĿǰÒѽøÈëÁÙ´²½×¶ÎµÄPSMAË«°Ð×éºÏ°üÀ¨PSMA/CD3¡¢PSMA/STEAP1¡¢PSMA/FAP¡¢PSMA/GRPRµÈ£¨¼û±í1£©¡£ÕâЩ˫°ÐµÄ×éºÏ²¢·ÇżȻ£¬¶øÊÇ»ùÓÚ¶ÔÖ×Áö·¢Éú·¢Õ¹»úÖÆ¡¢¸÷°ÐµãÉúÎïѧ¹¦ÄܵÄÉîÈëÑо¿¡£ÒÔPSMAºÍ³ÉÏËάϸ°û»î»¯µ°°×-A£¨fibroblast activation protein£¬FAP£©ÎªÀý£¬PSMAÔÚPCaϸ°û±íÃæ±í´ï£¬¶øÑо¿ÏÔʾ^[8]£¬FAPÔÚ¶àÖÖÖ×Áöϸ°û£¨°üº¬PCa£©µÄ»ùÖÊÖи߱í´ï£¬¾Ö²¿PCaÖÐFAP±í´ïˮƽ½ÏµÍ£¬¶øÍíÆÚPCaÖÐFAP±í´ïÏÔÖøÉý¸ß£¬ÇÒÔÚPSMAÒõÐÔµÄCRPCÖУ¬58%µÄ»¼ÕßFAPµÄ±í´ï³ÊÑôÐÔ£¬£¨¼ûͼ4£©ÓÉÓÚCRPCÔÚÖÎÁÆѹÁ¦Ï¿ÉÄÜʧȥPSMA±í´ï£¬¹Ê´ËFAP¿ÉÔÚÍíÆÚCRPC»¼ÕßÖÐ×÷ΪÌæ´úPSMA»òÓëPSMAÁªºÏ³ÉÏñºÍÖÎÁƵIJ¹³ä¡£

 

±í1 ´¦ÓÚÁÙ´²½×¶ÎµÄPSMAË«°ÐÒ©Îï

ͼ4 ×óͼ£ºPSMAÒõÐÔºÍPSMAÑôÐÔCRPCÖÐFAP ÑôÐÔ²¡ÀýµÄ±ÈÀý£»ÓÒͼ£ºPSMAÒõÐÔºÍPSMAÑôÐÔCRPCÖÐFAPµÄ±í´ïˮƽ

 

3¡¢½áÓͻÆÆ Pluvicto^@ÖÎÁÆÆ¿¾±£¬ÂõÏò mCRPC ¾«×¼ÖÎÁÆÐÂÕ÷³Ì

        ×ÛÉÏËùÊö£¬PSMAÔÚPCaϸ°ûÖеıí´ïÌØÕ÷ÊÇÖÆÔ¼Pluvicto^@ÖÎÁÆÏìÓ¦ÂʵĺËÐÄÒòËØ¡£¾ßÌå¶øÑÔPSMA µÄ±í´ïÒìÖÊÐÔÏÔÖø£¬²»½ö²»Í¬»¼Õß¡¢²»Í¬×ªÒÆÔîÖ®¼äµÄ PSMA ±í´ïˮƽ²îÒìÃ÷ÏÔ£¬¼´±ãÔÚͬһ²¡ÔîÄÚ£¬Ò²¿ÉÄܳöÏÖ PSMA ¸ß±í´ïÓëµÍ±í´ïÉõÖÁÒõÐÔÇøÓò²¢´æµÄÇé¿ö£¬ÕâÖ±½Óµ¼Ö°ÐÏòÒ©ÎïÄÑÒÔÈ«Ãæ¡¢ÌØÒìÐԵؽáºÏÖ×Áöϸ°û£¬´ó·ùÏ÷ÈõÁËÖÎÁÆЧ¹û£»µ±PSMA±í´ïˮƽ²»×ãʱ£¬Ò©ÎïÎÞ·¨ÓÐЧ¸»¼¯ÓÚÖ×Áö²¿Î»£¬»¼ÕßµÄÉú´æÆÚÒ²ËæÖ®ÏÔÖøËõ¶Ì£¬³ä·ÖÓ¡Ö¤Á˵°°×±í´ïÁ¿¶ÔÖÎÁÆЧ¹ûµÄ¹Ø¼üÓ°Ï죻ÔÚÖÎÁƹý³ÌÖУ¬PSMA ±í´ï»¹»á³öÏÖ¶¯Ì¬Ï½µµÄÇ÷ÊÆ£¬Ê¹µÃÖ×Áö¶ÔÒ©ÎïµÄÉãÈ¡Á¿Öð²½¼õÉÙ£¬Ôì³ÉºóÐøÖÎÁÆÁÆЧ˥¼õ¡£

        ΪͻÆÆÕâÒ»ÖÎÁÆÀ§¾³£¬ÁªºÏÓÃҩͨ¹ý²»Í¬×÷ÓûúÖÆÒ©ÎïµÄЭͬÔöЧ£¬ÓÐЧÑÓ³¤ÁË»¼ÕßµÄÎÞ½øÕ¹Éú´æÆÚ£¬²¢ÏÔÖøÌá¸ßÁ˿͹ۻº½âÂÊ£¬ÎªÌáÉýÖÎÁÆЧ¹ûÌṩÁËÓÐÁ¦Ö§³Å£»αºËËØƾ½èÆä¸üÇ¿µÄɱÉËÐԺ͸ü¾«×¼µÄ×÷Ó÷¶Î§£¬ÔÚ¸ÄÉÆÁÆЧ·½ÃæÕ¹ÏÖ³ö¾Þ´óDZÁ¦£¬È»¶ø£¬ÆäÆÕ¼°È´ÊÜÏÞÓÚ¹©Ó¦²»×ãÕâÒ»ÏÖʵÄÑÌ⣻¶øË«ÌØÒìÐÔ·ÅÉäÐÔºËËØÅäÌåÔòͨ¹ý¶à°ÐµãЭͬ£¬ÃÖ²¹Á˵¥Ò»PSMA°ÐÏòµÄȱÏÝ£¬ÎªPSMAÒõÐÔ»òµÍ±í´ï»¼ÕßÌṩÁËеÄÖÎÁÆ¿ÉÄÜ¡£

        δÀ´£¬Ëæ×ŶÔÖ×Áö΢»·¾³¸´ÔÓÐÔ¡¢°Ðµã¼ä»¥×÷»úÖÆÑо¿µÄ²»¶ÏÉîÈ룬ÒÔ¼°ÁÙ´²×ª»¯¼¼ÊõµÄ³ÖÐø½ø²½£¬ÁªºÏÖÎÁÆ·½°¸µÄ¾«Ï¸»¯ÓÅ»¯¡¢αºËËØÉú²ú¼¼ÊõµÄÍ»ÆÆÐÔ½øÕ¹ÒÔ¼°Ë«°ÐÅäÌåµÄ´ó¹æÄ£ÁÙ´²ÑéÖ¤£¬½«³ÉΪ¸ÃÁìÓòµÄÖصãÑо¿·½Ïò¡£ÕâЩ̽Ë÷²»½öÓÐÍû½øÒ»²½ÌáÉý Pluvicto^@µÄÖÎÁÆÏìÓ¦ÂÊ£¬¸ü½«ÎªmCRPC»¼ÕߵĸöÌ廯ÖÎÁÆ¿ª±Ùȫз¾¶£¬Íƶ¯ mCRPCµÄÖÎÁÆ´Ó“ÄÑÖΔÖð²½ÂõÏò“¿É¿Ø”£¬²¢³¯×Å“¿ÉÓú”µÄÖÕ¼«Ä¿±êÎȲ½Ç°½ø¡£

 

²Î¿¼ÎÄÏ×

• 1.ASCO 2025: How to Get Lutetium-177 PSMA to Those That Will Most Benefit?
• 2.Sayar E, Patel RA, Coleman IM, Roudier MP, Zhang A, Mustafi P, Low JY, Hanratty B, Ang LS, Bhatia V, Adil M, Bakbak H, Quigley DA, Schweizer MT, Hawley JE, Kollath L, True LD, Feng FY, Bander NH, Corey E, Lee JK, Morrissey C, Gulati R, Nelson PS, Haffner MC. Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer. JCI Insight. 2023 Apr 10;8(7):e162907.
• 3.Seifert R, Seitzer K, Herrmann K, Kessel K, Sch?fers M, Kleesiek J, Weckesser M, Boegemann M, Rahbar K. Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving 177Lu-PSMA-617 Radioligand Therapy. Theranostics. 2020 Jun 19;10(17):7812-7820.
• 4.Siebinga H, de Wit-van der Veen BJ, de Vries-Huizing DMV, Vogel WV, Hendrikx JJMA, Huitema ADR. Quantification of biochemical PSA dynamics after radioligand therapy with [177Lu]Lu-PSMA-I&T using a population pharmacokinetic/pharmacodynamic model. EJNMMI Phys. 2024 Apr 24;11(1):39. 
• 5. Hope TA, Antonarakis ES, Bodei L, Calais J, Iravani A, Jacene H, Koo PJ, Morgans AK, Osborne JR, Tagawa ST, Taplin ME, Sartor O, Morris MJ. SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy. J Nucl Med. 2023 Sep;64(9):1417-1423. 
• 6.Jadvar H, Rahbar K, Ahmadzadehfar H, Heidari P, Esfahani SA, Afshar-Oromieh A, Iravani A. Combination prostate-specific membrane antigen-targeted radiopharmaceutical therapy in metastatic prostate cancer. Q J Nucl Med Mol Imaging. 2025 Jun;69(2):174-179.
• 7.Rosar F, Hau F, Bartholom? M, Maus S, Stemler T, Linxweiler J, Ezziddin S, Khreish F. Molecular imaging and biochemical response assessment after a single cycle of [225Ac]Ac-PSMA-617/[177Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [177Lu]Lu-PSMA-617 monotherapy. Theranostics. 2021 Feb 16;11(9):4050-4060.
• 8. Huang RR, Zuo C, Mona CE, Holzgreve A, Morrissey C, Nelson PS, Brady L, True L, Sisk A, Czernin J, Calais J, Ye H. FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study. J Nucl Med. 2024 Dec 3;65(12):1952-1958.

*ÉùÃ÷£º±¾ÎĽöÊǽéÉÜÒ½Ò©¼²²¡ÁìÓòÑо¿½øÕ¹»ò¼òÊöÑо¿¸Å¿ö»ò·ÖÏíÒ½Ò©Ïà¹ØѶϢ£¬²¢·ÇÒ²²»»á½øÐÐÖÎÁÆ»òÕï¶Ï·½°¸ÍƼö£¬Ò²²»¶ÔÏà¹ØͶ×ʹ¹³ÉÈκν¨Òé¡£